Redeye provides commentary on Sivers' pre-announced figures for 2023.
Q4 report due 21 Feb Q4'23e net sales SEK 195m, EBITA SEK 25m We raise our fair value range to SEK 2...
Huddlestock announced on Thursday, January the 9th, that German Huddlestock GmbH has signed a Letter...
Redeye is positive about SenzaGen’s GARDskin order worth SEK1.
Redeye embraces the reported data from OssDsign’s TOP FUSION clinical study, and we await further pe...
Fiskars has completed the purchase price allocation of the Georg Jensen acquisition and recognizes n...
Redeye updates its estimates for Lagercrantz following a Q3 acquisition spree, along with FX adjustm...
Lyckegård Group AB (”Lyckegård” eller ”bolaget”) meddelade den 8 januari år 2024 att bolaget avser r...
Avtech announced it has signed a two-year agreement with SAS with an expected value of SEK5.
Calliditas published a preliminary Q4 update earlier today.
Hours before the Christmas weekend, GRANGEX announced a Royalty and off-take agreement with Anglo Am...
Redeye briefly comments on the announcement of an indication expansion made by Initiator Pharma earl...
Redeye comments on NeoDynamics’ rights issue of approximately SEK25m.
Redeye comments on Nito Games' preliminary figures for Q4, which exceed our expectations by 20% on t...
Q4e: 3.5% y-o-y revenue decline, 16.7% EBITDA margin Updating estimates after close of SDR acquisiti...
Redeye in this note briefly comments on the latest happenings in the 879 patent litigation process.
Q4 report due on Tuesday 6 February No major estimate changes, bid still in focus 12x '24e EV/EBIT, ...
Redeye adjusts its estimates following ADDvise’s recent announcement of the acquisitions of Axeleris...
IRLAB Therapeutics has announced a new loan facility of up to SEK55m with Formue Nord to support its...
Redeye is intrigued by today’s news that Saniona has selected an additional clinical candidate, the ...
